The U.S. Food and Drug Administration (FDA) has approved vepdegestrant, the world's first therapy built on PROTAC (Proteolysis-Targeting Chimera) technology.
- Vepdegestrant is an oral drug developed by Arvinas and Pfizer.
- It is meant for ESR1-mutated, ER-positive (Estrogen Receptor-positive), HER2-negative advanced breast cancer.
- PROTAC drugs work by targeting disease-causing proteins for breakdown inside cells.
The approval marks the first clinical use of the PROTAC approach, a new class of targeted medicines.